ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements
Indrayani Biotech filed its quarterly shareholding pattern for 30 September 2026. Promoter group holds 32.89% of equity; this is routine compliance with no corporate event.
Indrayani Biotech has filed its 34th Annual Report for FY2025-26, containing the AGM notice for 30 November 2026 by VC/OAVM. The chairman notes a Rights Issue was initiated in October 2026 to raise capital.
Indrayani Biotech's 34th AGM is set for 30 November 2026, with book closure from 24 to 30 November. Remote e-voting runs 27 to 29 November 2026.
Indrayani Biotech appointed Ms. N.S. Poornima as Secretarial Auditor and accepted the resignation of Company Secretary C.S. Shanmuga Sundar effective 2 Nov 2026. The KMP departure due to personal health is the material change.
Indrayani Biotech allotted 83,64,036 rights equity shares at Rs 15 (75,03,333 fully paid) and Rs 3.75 (8,60,703 partly paid). Issue receipts total about Rs 11.58 Crore.
Indrayani Biotech's committee allotted 83,64,036 partly paid rights shares at Rs.15 each, worth about Rs.12.55 crore. Application money of Rs.3.75 per share has been received.
Indrayani Biotech Ltd has scheduled a Board meeting for November 06, 2026. The meeting will primarily consider the notice for the company's 34th Annual General Meeting.
Indrayani Biotech appointed Ms. N. S. Poornima as Secretarial Auditor for FY 2025-26 to fill a casual vacancy. Company Secretary C.S. Shanmuga Sundar's resignation took effect on 2 November 2026.
Indrayani Biotech received a tax recovery notice for outstanding demands totaling ₹1.17 Crore for various assessment years, for which the company has filed responses.
Independent Director Mr. K.S. Vaidyanathan has resigned from the Board of Indrayani Biotech Limited, effective October 13, 2026, due to personal reasons.
Indrayani Biotech Limited submitted the quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Indrayani Biotech Ltd reported revenue from operations of ₹37.7 Cr (+29.6% YoY) and net profit of ₹0.5 Cr (+150.0% YoY) for Q1 FY27.
Indrayani Biotech sold shares of its subsidiary, Dindigul Farm Product Limited, to the open market. This divestment marks a reduction in the company's subsidiary holding.
Indrayani Biotech will hold a board meeting on October 7, 2026, to consider the company's unaudited financial results for the quarter ended June 30, 2026.
Indrayani Biotech announced its Rights Issue of up to 3.25 crore partly paid-up equity shares at ₹15 per share, aggregating to ₹48.79 Crore.
Indrayani Biotech Ltd has revised the schedule for its rights issue. The issue will now be open from September 15, 2026, to October 14, 2026.
Indrayani Biotech Ltd announced the resignation of Mr. K. Ravichandran as its Secretarial Auditor, effective August 6, 2026. The company will appoint a successor in due course.
Indrayani Biotech received approval from the Registrar of Companies to extend the deadline for its FY 2025-26 Annual General Meeting by two months, until November 30, 2026.
Indrayani Biotech Ltd reported revenue from operations of ₹37.8 Cr (-25.3% YoY) and net profit of ₹1 Cr for Q4 FY26.
Indrayani Biotech Ltd reported revenue from operations of ₹72.8 Cr (+43.9% YoY) and net profit of ₹1.1 Cr for Q4 FY26.
Indrayani Biotech Ltd has scheduled a Board of Directors meeting for August 17, 2026, to consider and approve the audited financial results for the year ended March 31, 2026.
A quarterly shareholding pattern filing by Indrayani Biotech Ltd for the period ending June 30, 2026.
Indrayani Biotech announced that the Income Tax Appellate Tribunal quashed a prior assessment order. The matter is restored to the First Appellate Authority for fresh adjudication.
Indrayani Biotech reported a delay in submitting its FY26 audited financial results due to subsidiary consolidation and audit disruptions. The trading window remains closed for designated persons.
Mr. S. Indirakumar resigned as Whole-Time Director, alleging severe governance lapses and financial mismanagement. The resignation highlights significant internal conflict and potential regulatory risks.
Indrayani Biotech revised its Rights Issue schedule to June 25 – July 24, 2026. This administrative update adjusts the capital raising timeline for eligible equity shareholders.
Indrayani Biotech Limited's Rights Issue Committee has approved the Letter of Offer, Abridged Letter of Offer, and Composite Application Form for its proposed rights issue. This marks a key procedural milestone in the company's capital-raising process.
Indrayani Biotech Ltd has filed an appeal before the Income Tax Appellate Tribunal (ITAT) against an assessment order raising a demand of ₹13.90 Crore for AY 2023-24. The company, advised by legal counsel, expects no material adverse impact on its financial operations as the matter remains sub-judice.
Indrayani Biotech Ltd has announced the ISIN (INE007C20013) for its upcoming Rights Entitlement. The issue involves partly paid-up equity shares with a face value of Rs.10 and a paid-up value of Rs.2.50 each. This follows the board's approval on April 9, 2026, for raising capital through a rights issue.
Indrayani Biotech Limited has fixed April 28, 2026, as the record date for its ₹48.79 Crore rights issue. Eligible shareholders will receive 5 rights shares for every 7 shares held at an issue price of ₹15 per share.